← Eichor
Condition: Relapsed And Refractory Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed And Refractory

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Im
Phase 2 · 1 location(s) · Diwakar Davar · NCT06499896CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Phase 1/Phase 2 · 2 location(s) · Uppsala University · NCT06002659Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Phase 2 · 1 location(s) · Ruijin Hospital · NCT05348213SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid T
Phase 1 · 11 location(s) · Qurgen Inc. · NCT06873659Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06464861Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07240974Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT05271292Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
EARLY_Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07626476A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 4 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07493135Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 · 11 location(s) · Juventas Cell Therapy Ltd. · NCT04684147Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell L
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07164560In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT05436223Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Phase 1/Phase 2 · 1 location(s) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · NCT05869279A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilz
Phase 1/Phase 2 · 84 location(s) · BeOne Medicines · NCT04973605Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04322383A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · NCT07093073A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 15 location(s) · Shanghai AbelZeta Ltd. · NCT05800977A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07500753Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed
Phase 2 · 1 location(s) · Naresh Bumma · NCT07657312Novel Digital Application for Patients With Acute Leukemia
NA · 3 location(s) · Massachusetts General Hospital · NCT06472128ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Phase 2 · 11 location(s) · Hansoh BioMedical R&D Company · NCT05830123A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Sol
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06006273A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants
Phase 1/Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT05533775Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06995872
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.